Laquinimod
Oral agent that affects the immune system
Phase II trial with 306 patients, 24 weeks
Relapse rate reduced 32%
MRI activity reduced 38%
Starting Phase III
Minocycline
Oral antibiotic which has anti-inflammatory properties and good CNS
penetration
Phase II study with 40 subjects, GA+minocycline vs. GA alone, 9 months
Relapse rate reduced 42%
MRI activity reduced
65%
Fingolimod
Affects circulation of lymphocytes, traps them in the lymph node
Oral
Phase II study, 281 patients, 6 months
Relapse rate reduced 55%
MRI activity reduced
80%*
Starting Phase III
Rituximab
Monoclonal antibody specific for B cells
104 patients, 48 weeks
Relapse rate reduced 56%
MRI activity decreased 91%
Going to Phase III
Alemtuzumab
Monoclonal antibody against CD52 (found
on many WBC)
334 patients, 2 years, compared to Rebif
Relapse rate reduced 75% *
Disability reduced 65%
3% ITP (one death), 15% Grave’s